Patent ID: 9540695
Date: 2017-01-10
CPC Classifications: A61K,A61P,C12Q

Claim:
1. A method of prognosing progression of platinum-resistant stage III ovarian cancer in response to platinum-based chemotherapy in a human subject in need thereof, comprising: (a) obtaining an ovarian tumor sample from the subject; (b) determining the expression of the microRNA molecule of SEQ ID NO: 4 in said sample by a method comprising contacting microRNA molecules from the ovarian tumor sample with a probe attached to a solid substrate, wherein the probe consists of the complement of SEQ ID NO: 4 and a linker of 10-60 nucleotides at the 3′ end of the complement; (c) comparing said expression to a threshold expression and determining if the expression of SEQ ID NO: 4 in said sample is above said threshold expression; (d) prognosing progression of platinum-resistant stage III ovarian cancer in response to platinum-based chemotherapy in the subject based on increased expression of SEQ ID NO: 4 in the sample relative to the threshold expression wherein the increase in expression of SEQ ID NO: 4 is prognostic of progression of platinum-resistant stage III ovarian cancer, wherein platinum resistance comprises partial response or recurrence of ovarian cancer within 6 months of the end of the platinum-based chemotherapy for the ovarian cancer, and wherein the increase in expression of SEQ ID NO: 4 is relative to the threshold expression, wherein the threshold is the expression of SEQ ID NO: 4 in a platinum-sensitive ovarian cancer, wherein platinum sensitivity comprises complete response to platinum-based chemotherapy with no recurrence of ovarian cancer within 6 months of the end of the chemotherapy for the ovarian cancer.